Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.76 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.35 | 10.36 | 12.98 | 5.17 | 0.86 | 1152.76 | 187.32 | 133.92 | 3.45 | 29.84 | 50.87 | 12.68 | 23.34 |
| — | -99.1% | -93.1% | -96.1% | -75.1% | +3763.4% | +268.3% | +956.0% | -85.2% | -99.4% | +59.4% | -73.6% | -35.9% | |
| P/B Ratio | 1.35 | 23.24 | 9.68 | 1.54 | 0.78 | 1.60 | 1.66 | 2.07 | 2.37 | 1.77 | 1.47 | 1.57 | 1.69 |
| — | +1351.0% | +484.1% | -25.3% | -67.0% | -9.4% | +12.8% | +31.2% | +40.2% | -12.9% | -15.8% | -38.0% | -48.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Editas Medicine, Inc.'s operating margin was -325.4% in Q3 2025, up 1115.1 pp QoQ and up 107323.7 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -888.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 104.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2521.3% | -176.8% | -24.1% | 97.6% | 71.6% | -931.5% | -283.8% | -695.6% |
| — | +104.0% | +156.6% | +514.2% | +2.5% | -3620.1% | +81.0% | +91.5% | +114.0% | +100.1% | -58.9% | +38.4% | -245.8% | |
| Operating Margin | -777.2% | -325.4% | -1440.6% | -1635.1% | -152.2% | -107649.2% | -14016.2% | -5902.3% | -39.9% | -940.1% | -1527.3% | -517.3% | -970.7% |
| — | +99.7% | +89.7% | +72.3% | -281.5% | -11351.0% | -817.7% | -1040.9% | +95.9% | +99.3% | -79.2% | +31.0% | -190.9% | |
| Net Margin | -733.7% | -333.0% | -1487.8% | -1633.5% | -148.3% | -101870.5% | -13178.8% | -5458.1% | -31.4% | -843.7% | -1395.6% | -497.8% | -929.3% |
| — | +99.7% | +88.7% | +70.1% | -371.9% | -11974.5% | -844.3% | -996.5% | +96.6% | +99.4% | -66.1% | +33.3% | -179.6% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -98.1% | -153.9% | -130.5% | -77.4% | -29.3% | -30.5% | -25.7% | -19.3% | -5.3% | -11.8% | -11.2% | -14.5% | -15.7% |
| — | -404.8% | -407.9% | -301.8% | -450.7% | -157.5% | -128.7% | -33.1% | +66.0% | +6.5% | -2.8% | -52.6% | -115.6% | |
| ROA | -56.4% | -12.2% | -22.5% | -25.1% | -13.6% | -17.4% | -16.4% | -13.2% | -3.8% | -8.6% | -8.0% | -10.0% | -11.6% |
| — | +30.2% | -37.0% | -90.7% | -260.8% | -102.8% | -104.6% | -31.6% | +67.6% | +14.2% | +9.8% | -29.0% | -95.5% | |
| ROIC | -120.8% | — | — | — | -44.8% | -30.3% | -23.2% | -18.8% | -6.1% | -14.2% | -15.0% | -15.6% | -19.5% |
| — | — | — | — | -630.8% | -113.3% | -54.8% | -20.5% | +68.5% | +10.7% | -18.0% | -44.2% | -128.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 23.6% YoY to 2.86x, tightening the short-term liquidity position. Debt/Equity has risen for 7 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 1.46 | 1.10 | 0.50 | 0.26 | 0.22 | 0.17 | 0.12 | 0.14 | 0.10 | 0.09 | 0.12 | 0.12 |
| — | +566.6% | +560.3% | +330.1% | +87.6% | +128.2% | +79.4% | -0.9% | +14.1% | +87.0% | +113.6% | +159.0% | +155.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.75 | 2.86 | 2.77 | 3.08 | 3.75 | 3.75 | 3.85 | 4.60 | 5.39 | 6.12 | 8.09 | 5.68 | 5.94 |
| — | -23.6% | -28.1% | -33.1% | -30.5% | -38.8% | -52.4% | -19.0% | -9.2% | -39.3% | -36.1% | -58.3% | -45.2% | |
| Quick Ratio | 3.75 | 2.86 | 2.77 | 3.08 | 3.75 | 3.75 | 3.85 | 4.60 | 5.39 | 6.12 | 8.09 | 5.68 | 5.94 |
| — | -23.6% | -28.1% | -33.1% | -30.5% | -38.8% | -52.4% | -19.0% | -9.2% | -39.3% | -36.1% | -58.3% | -45.2% | |
| Interest Coverage | — | -10.23 | -25.52 | -34.37 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonEditas Medicine, Inc.'s current P/E is -0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Editas Medicine, Inc.'s current operating margin is -777.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Editas Medicine, Inc.'s business trajectory between earnings reports.